Refine
Year of publication
Document Type
- Article (82)
- Preprint (30)
- Conference Proceeding (1)
Language
- English (113) (remove)
Has Fulltext
- yes (113)
Is part of the Bibliography
- no (113)
Keywords
- COVID-19 (5)
- SARS-CoV-2 (4)
- (surface) partial differential equations (3)
- Finite Volumes (3)
- Liver cirrhosis (3)
- computational virology (3)
- massively parallel multigrid solvers (3)
- realistic geometries (3)
- viral dynamics (3)
- 3D spatio-temporal resolved mathematical models (2)
- HIV (2)
- Patient blood management (2)
- clinical immunology (2)
- elderly (2)
- hepatitis C virus (2)
- hepatitis C virus (HCV) (2)
- immune reconstitution (2)
- influenza (2)
- mathematical models of viral RNA cycle (2)
- out-patient paediatrics (2)
- respiratory tract infection (2)
- sphingolipid (2)
- within-host viral modelling (2)
- 3D laparoscopy (1)
- 3D spatiotemporal resolved mathematical models (1)
- ATM (1)
- Acoustics (1)
- Acute respiratory distress syndrom (1)
- Age estimation (1)
- Aging (1)
- Alcoholic liver disease (1)
- Allergic rhinitis (1)
- Analysis tool (1)
- Antibody therapy (1)
- Aspergillus fumigatus (1)
- Ataxia telangiectasia (1)
- BNT162b2 (1)
- Bamlanivimab (1)
- Blood loss estimation (1)
- Blow flies (1)
- CD3/19 depletion (1)
- CD34 selection (1)
- COVID 19 (1)
- CRM (1)
- CVID (1)
- Caco-2 cells (1)
- Cancer detection and diagnosis (1)
- Cancer treatment (1)
- Capnography (1)
- Casirivimab (1)
- Cell motility (1)
- Cell salvage (1)
- Cell-to-Cell Spread (1)
- ChAdOx1-S (1)
- Chronic heart failure (1)
- Colorectal cancer (1)
- Colorimetric blood loss estimation (1)
- Comprehensive complication index (1)
- Compression stocking (1)
- Computed axial tomography (1)
- Cytology (1)
- Cytoskeletal proteins (1)
- DHA (1)
- Deep vein thrombosis (1)
- Deformation (1)
- Direct measurement (1)
- Double-blind placebo-controlled trial (1)
- EPA (1)
- Early goal-directed therapy (1)
- Electron-pion identification (1)
- Ellipsoids (1)
- Endoscopy (1)
- Epidural block (1)
- European Society for Immunodeficiencies (ESID) (1)
- Exercise challenge (1)
- Exercise challenge at an ambient temperature (1)
- Exercise challenge in a cold chamber (1)
- Exercise-induced asthma (1)
- Exercise-induced bronchoconstriction (1)
- Exhaled nitric oxide (1)
- Fibre/foam sandwich radiator (1)
- Fibrotest (1)
- Forced expiratory volume in 1 s (1)
- Forensic entomology (1)
- GVHD (1)
- Genetic testing (1)
- German PID-NET registry (1)
- Gravimetric method (1)
- H1N1 (1)
- HCV (1)
- HSCT (1)
- Hemagglutination inhibition assay (1)
- Hemorrhage (1)
- Hepatitis (1)
- Hepatocellular carcinoma (1)
- Hepatotoxicity (1)
- Heterologous prime-boost (1)
- House dust mite allergy (1)
- Hypoxia (1)
- IgE (1)
- IgG substitution therapy (1)
- IgG4-related disease (1)
- Imdevimab (1)
- Immune suppression (1)
- Immunogenicity (1)
- Immunohistochemistry techniques (1)
- Immunology (1)
- In-line filtration (1)
- Indeterminate biliary stricture (1)
- Inflammation (1)
- Infusion management (1)
- Integrated Pulmonary Index (1)
- Intensive care (1)
- Intensive care unit (1)
- Intensive care units (1)
- Interleukin-22 (1)
- Intubation (1)
- Ionisation energy loss (1)
- LC–MS/MS (1)
- Linear regression analysis (1)
- Liver diseases (1)
- Liver enzymes (1)
- Liver transplantation (1)
- Liver-related complications (1)
- LncRNA (1)
- Local IgE (1)
- Local allergic rhinitis (1)
- Longchain polyunsaturated fatty acids (1)
- MELD (1)
- Medical ethics (1)
- Metastasis (1)
- Metastatic tumors (1)
- Methacholine challenge test (1)
- MitraClip (1)
- Monitoring (1)
- Morbidity (1)
- Mortality (1)
- Multi-wire proportional drift chamber (1)
- NK cell (1)
- NK cell subset (1)
- Neural network (1)
- Nkx2-5 (1)
- Non-allergic-rhinitis (1)
- Nox4 (1)
- Opioids (1)
- Organ dysfunction (1)
- PCR (1)
- PID prevalence (1)
- Particles (1)
- Percutaneous endoscopic gastrostomy (1)
- Portal hypertension (1)
- Post-mortem interval (1)
- Primary prophylaxis (1)
- Propensity score matching (1)
- Pulmonary artery pressure (1)
- Pulmonary embolism (1)
- Radiation exposure (1)
- Reactogenicity (1)
- Regression analysis (1)
- Remote monitoring (1)
- S1P (1)
- SCT (1)
- SR-BI (1)
- SVR (1)
- SW480 cells (1)
- Sedation (1)
- Sedatives (1)
- Sepsis-bundle (1)
- Spontaneous bacterial peritonitis (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- TR (1)
- Thyroid (1)
- Tracking (1)
- Transfusion (1)
- Transient elastography (1)
- Transition radiation detector (1)
- Trigger (1)
- Ultrasound imaging (1)
- Venous thromboembolism (1)
- Ventilators (1)
- Viral load (1)
- Visual estimation (1)
- Volumetric analysis (1)
- Xenon-based gas mixture (1)
- acoustic radiation force impulse (1)
- acute cholecystitis (1)
- acute lung injury (1)
- acute respiratory distress syndrome (1)
- allogeneic stem cell transplantation (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- ataxia score (1)
- ataxia telangiectasia (1)
- basic mechanisms (1)
- bevacizumab (1)
- bile duct stenosis (1)
- biomarker (1)
- body plethysmography (1)
- bronchial allergen provocation (1)
- cART (1)
- cardiac surgery (1)
- cell salvage (1)
- cells (1)
- ceramide (1)
- chemotherapy (1)
- children (1)
- chronic hepatitis C (1)
- chronic inflammation (1)
- co-infection (1)
- critical care (1)
- cystic fibrosis (1)
- cytotoxicity (1)
- dE/dx (1)
- delayed cholecystectomy (1)
- dentin adhesives (1)
- direct-acting antiviral (DAA) treatment (1)
- direct-acting antivirals (1)
- early cholecystectomy (1)
- endoscopic retrograde cholangiopancreatography (1)
- endoscopy (1)
- eosinophilic cholangitis (1)
- fibroblasts (1)
- first-line chemotherapy (1)
- gallstone disease (1)
- gargle lavage (1)
- gender dysphoria (1)
- gender-affirming hormone therapy (1)
- hepatic fibrosis (1)
- hepatic steatosis (1)
- hepatitis C (1)
- hypertrophy (1)
- hypnotics and sedatives (1)
- immunity (1)
- immunosenescence (1)
- immunosuppression (1)
- in vitro (1)
- infection (1)
- inflammation (1)
- insulin resistance (1)
- intrahepatic cholangiocarcinoma (1)
- legal gender reassignment (1)
- liver cirrhosis (1)
- liver disease (1)
- liver fibrosis (1)
- lung function (1)
- lymphocytes (1)
- mechanical accuracy (1)
- metastatic colorectal cancer (1)
- mortality risk (1)
- multimorbidity (1)
- nasal swab (1)
- neurodegeneration (1)
- overall survival (1)
- oxLDL (1)
- parameter estimation (1)
- patient (1)
- patient blood management (1)
- phantom study (1)
- pneumocystis (1)
- population dynamics (1)
- portal hypertension (1)
- postinfectious bronchiolitis obliterans (1)
- primary immunodeficiency (PID) (1)
- primary sclerosing cholangitis (1)
- prone position (1)
- pulmonary ventilation (1)
- registry for primary immunodeficiency (1)
- renal transplantation (1)
- risk factors (1)
- robot-guided stereotaxy (1)
- saliva (1)
- screening (1)
- self-collected samples (1)
- severe acute respiratory syndrome coronavirus 2 (1)
- simulation (1)
- stereotactic frame (1)
- stereotactic neurosurgery (1)
- stroke (1)
- survival (1)
- thrombolysis (1)
- training (1)
- trans (1)
- transfusion (1)
- transient elastography (1)
- transplantation (1)
- transsexualism (1)
- ulcerative colitis (1)
- vaccination (1)
- within-host viral modeling (1)
Institute
- Medizin (79)
- Informatik (35)
- Frankfurt Institute for Advanced Studies (FIAS) (33)
- Physik (33)
- Georg-Speyer-Haus (2)
- Biochemie und Chemie (1)
- Biowissenschaften (1)
- Exzellenzcluster Herz-Lungen-System (1)
- Goethe-Zentrum für Wissenschaftliches Rechnen (G-CSC) (1)
- Institut für Ökologie, Evolution und Diversität (1)
Background & Aims: Hepatitis C virus (HCV) cell entry is mediated by several cell surface receptors, including scavenger receptor class B type I (SR-BI). Oxidized low density lipoprotein (oxLDL) inhibits the interaction between HCV and SR-BI in a noncompetitive manner. We tested whether serum oxLDL levels correlate with sustained virologic response (SVR) rates after interferon-based treatment of chronic hepatitis C.
Methods: Baseline oxLDL was determined in 379 participants with chronic HCV genotype 1 infection from the INDIV-2 study using a commercial enzyme-linked immunosorbent assay. The mechanistic in vitro studies used full-length and subgenomic HCV genomes replicating in hepatoma cells.
Results: In the multivariate analysis, oxLDL was found to be an independent predictor of SVR. Oxidized LDL did not correlate with markers of inflammation (alanine transaminase, ferritin), nor was serum oxLDL affected by exogenous interferon administration. Also, oxLDL did not alter the sensitivity of HCV replication to interferon. However, oxLDL was found to be a potent inhibitor of cell-to-cell spread of HCV between adjacent cells in vitro. It could thus reduce the rate at which new cells are infected by HCV through either the cell-free or cell-to-cell route. Finally, serum oxLDL was significantly associated with the estimated infected cell loss rate under treatment.
Conclusions: Oxidized LDL is a novel predictor of SVR after interferon-based therapy and may explain the previously observed association of LDL with SVR. Rather than being a marker of activated antiviral defenses it may improve chances of SVR by limiting spread of infection to naive cells through the cell-to-cell route.
Augmenting LTP-like plasticity in human motor cortex by spaced paired associative stimulation
(2015)
Paired associative stimulation (PASLTP) of the human primary motor cortex (M1) can induce LTP-like plasticity by increasing corticospinal excitability beyond the stimulation period. Previous studies showed that two consecutive PASLTP protocols interact by homeostatic metaplasticity, but animal experiments provided evidence that LTP can be augmented by repeated stimulation protocols spaced by ~30min. Here we tested in twelve healthy selected PASLTP responders the possibility that LTP-like plasticity can be augmented in the human M1 by systematically varying the interval between two consecutive PASLTP protocols. The first PASLTP protocol (PAS1) induced strong LTP-like plasticity lasting for 30-60min. The effect of a second identical PASLTP protocol (PAS2) critically depended on the time between PAS1 and PAS2. At 10min, PAS2 prolonged the PAS1-induced LTP-like plasticity. At 30min, PAS2 augmented the LTP-like plasticity induced by PAS1, by increasing both magnitude and duration. At 60min and 180min, PAS2 had no effect on corticospinal excitability. The cumulative LTP-like plasticity after PAS1 and PAS2 at 30min exceeded significantly the effect of PAS1 alone, and the cumulative PAS1 and PAS2 effects at 60min and 180min. In summary, consecutive PASLTP protocols interact in human M1 in a time-dependent manner. If spaced by 30min, two consecutive PASLTP sessions can augment LTP-like plasticity in human M1. Findings may inspire further research on optimized therapeutic applications of non-invasive brain stimulation in neurological and psychiatric diseases.
Background: Sphingolipids constitute bioactive molecules with functional implications in liver homeostasis. Particularly, ablation of very long chain ceramides in a knockout mouse model has been shown to cause a severe hepatopathy.
Methods: We aimed to evaluate the serum sphingolipid profile of 244 patients with cirrhosis prospectively followed for a median period of 228±217 days via mass spectrometry.
Results: We thereby observed a significant decrease of long and very long chain ceramides, particularly of C24ceramide, in patients with increasing severity of cirrhosis (p<0.001). Additionally, hydropic decompensation, defined by clinical presentation of ascites formation, was significantly correlated to low C24ceramide levels (p<0.001) while a significant association to hepatic decompensation and poor overall survival was observed for low serum concentrations of C24ceramide (p<0.001) as well. Multivariate analysis further identified low serum C24ceramide to be independently associated to overall survival (standard beta = -0.001, p = 0.022).
Conclusions: In our current analysis serum levels of very long chain ceramides show a significant reciprocal correlation to disease severity and hepatic decompensation and are independently associated with overall survival in patients with cirrhosis. Serum sphingolipid metabolites and particularly C24ceramide may constitute novel molecular targets of disease severity, hepatic decompensation and overall prognosis in cirrhosis and should be further evaluated in basic research studies.
Background: Patients with liver cirrhosis have a highly elevated risk of developing bacterial infections that significantly decrease survival rates. One of the most relevant infections is spontaneous bacterial peritonitis (SBP). Recently, NOD2 germline variants were found to be potential predictors of the development of infectious complications and mortality in patients with cirrhosis. The aim of the INCA (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites) trial is to investigate whether survival of this genetically defined high-risk group of patients with cirrhosis defined by the presence of NOD2 variants is improved by primary antibiotic prophylaxis of SBP.
Methods/Design: The INCA trial is a double-blind, placebo-controlled clinical trial with two parallel treatment arms (arm 1: norfloxacin 400 mg once daily; arm 2: placebo once daily; 12-month treatment and observational period). Balanced randomization of 186 eligible patients with stratification for the protein content of the ascites (<15 versus ≥15 g/L) and the study site is planned. In this multicenter national study, patients are recruited in at least 13 centers throughout Germany. The key inclusion criterion is the presence of a NOD2 risk variant in patients with decompensated liver cirrhosis. The most important exclusion criteria are current SBP or previous history of SBP and any long-term antibiotic prophylaxis. The primary endpoint is overall survival after 12 months of treatment. Secondary objectives are to evaluate whether the frequencies of SBP and other clinically relevant infections necessitating antibiotic treatment, as well as the total duration of unplanned hospitalization due to cirrhosis, differ in both study arms. Recruitment started in February 2014.
Discussion: Preventive strategies are required to avoid life-threatening infections in patients with liver cirrhosis, but unselected use of antibiotics can trigger resistant bacteria and worsen outcome. Thus, individualized approaches that direct intervention only to patients with the highest risk are urgently needed. This trial meets this need by suggesting stratified prevention based on genetic risk assessment. To our knowledge, the INCA trial is first in the field of hepatology aimed at rapidly transferring and validating information on individual genetic risk into clinical decision algorithms.
Trial registrations: German Clinical Trials Register DRKS00005616. Registered 22 January 2014. EU Clinical Trials Register EudraCT 2013-001626-26. Registered 26 January 2015.
Altered mucosal immune response after acute lung injury in a murine model of Ataxia Telangiectasia
(2014)
Background: Ataxia telangiectasia (A-T) is a rare but devastating and progressive disorder characterized by cerebellar dysfunction, lymphoreticular malignancies and recurrent sinopulmonary infections. In A-T, disease of the respiratory system causes significant morbidity and is a frequent cause of death.
Methods: We used a self-limited murine model of hydrochloric acid-induced acute lung injury (ALI) to determine the inflammatory answer due to mucosal injury in Atm (A-T mutated)- deficient mice (Atm−/−).
Results: ATM deficiency increased peak lung inflammation as demonstrated by bronchoalveolar lavage fluid (BALF) neutrophils and lymphocytes and increased levels of BALF pro-inflammatory cytokines (e.g. IL-6, TNF). Furthermore, bronchial epithelial damage after ALI was increased in Atm−/− mice. ATM deficiency increased airway resistance and tissue compliance before ALI was performed.
Conclusions: Together, these findings indicate that ATM plays a key role in inflammatory response after airway mucosal injury.
Background: Ribavirin (RBV) remains part of several interferon-free treatment strategies even though its mechanisms of action are still not fully understood. One hypothesis is that RBV increases responsiveness to type I interferons. Pegylated Interferon alpha (PEG-IFNa) has recently been shown to alter natural killer (NK) cell function possibly contributing to control of hepatitis C virus (HCV) infection. However, the effects of ribavirin alone or in combination with IFNa on NK cells are unknown.
Methods: Extensive ex vivo phenotyping and functional analysis of NK cells from hepatitis C patients was performed during antiviral therapy. Patients were treated for 6 weeks with RBV monotherapy (n = 11), placebo (n = 13) or PEG-IFNa-2a alone (n = 6) followed by PEG-IFNa/RBV combination therapy. The effects of RBV and PEG-IFNa-2a on NK cells were also studied in vitro after co-culture with K562 or Huh7.5 cells.
Results: Ribavirin monotherapy had no obvious effects on NK cell phenotype or function, neither ex vivo in patients nor in vitro. In contrast, PEG-IFNa-2a therapy was associated with an increase of CD56bright cells and distinct changes in expression profiles leading to an activated NK cell phenotype, increased functionality and decline of terminally differentiated NK cells. Ribavirin combination therapy reduced some of the IFN effects. An activated NK cell phenotype during therapy was inversely correlated with HCV viral load.
Conclusions: PEG-IFNa activates NK cells possibly contributing to virological responses independently of RBV. The role of NK cells during future IFN-free combination therapies including RBV remains to be determined.
Aim. To compare the efficacy, safety, and patient’s perception of two prostaglandin E2 application methods for induction of labour.
Method. Above 36th weeks of gestation, all women, who were admitted to hospital for induction of labour, were prospectively randomised to intravaginal 1 mg or intracervical 0.5 mg irrespective of cervical Bishop score. The main outcome variables were induction-to-delivery interval, number of foetal blood samples, PDA rate, rate of oxytocin augmentation, rate of vaginal delivery, and patient’s perception using semantic differential questionnaire.
Results. Thirty-nine patients were enrolled in this study. There was no statistical significant difference between the two groups in regard to perceptions of induction. The median induction delivery time using intravaginal versus intracervical administration was 29.9 versus 12.8 hours, respectively (). No statistically difference between the groups was detected in regard to parity, gestation age, cervical Bishop score, number of foetal blood samples, PDA rate, rate of oxytocin augmentation, and mode of birth.
Summary. Irrespective of the cervical Bishop Score, intracervical gel had a shorter induction delivery time without impingement on the women’s perception of induction.
Background: IL28B gene polymorphism is the best baseline predictor of response to interferon alfa-based antiviral therapies in chronic hepatitis C. Recently, a new IFN-L4 polymorphism was identified as first potential functional variant for induction of IL28B expression. Individualization of interferon alfa-based therapies based on a combination of IL28B/IFN-L4 polymorphisms may help to optimize virologic outcome and economic resources.
Methods: Optimization of treatment outcome prediction was assessed by combination of different IL28B and IFN-L4 polymorphisms in patients with chronic HCV genotype 1 (n = 385), 2/3 (n = 267), and 4 (n = 220) infection treated with pegylated interferon alfa (PEG-IFN) and ribavirin with (n = 79) or without telaprevir. Healthy people from Germany (n = 283) and Egypt (n = 96) served as controls.
Results: Frequencies of beneficial IL28B rs12979860 C/C genotypes were lower in HCV genotype 1/4 infected patients in comparison to controls (20–35% vs. 46–47%) this was also true for ss469415590 TT/TT (20–35% vs. 45–47%). Single interferon-lambda SNPs (rs12979860, rs8099917, ss469415590) correlated with sustained virologic response (SVR) in genotype 1, 3, and 4 infected patients while no association was observed for genotype 2. Interestingly, in genotype 3 infected patients, best SVR prediction was based on IFN-L4 genotype. Prediction of SVR with high accuracy (71–96%) was possible in genotype 1, 2, 3 and 4 infected patients who received PEG-IFN/ribavirin combination therapy by selection of beneficial IL28B rs12979860 C/C and/or ss469415590 TT/TT genotypes (p<0.001). For triple therapy with first generation protease inhibitors (PIs) (boceprevir, telaprevir) prediction of high SVR (90%) rates was based on the presence of at least one beneficial genotype of the 3 IFN-lambda SNPs.
Conclusion: IFN-L4 seems to be the best single predictor of SVR in genotype 3 infected patients. For optimized prediction of SVR by treatment with dual combination or first generation PI triple therapies, grouping of interferon-lambda haplotypes may be helpful with positive predictive values of 71–96%.
Background: Thyroid Imaging Reporting and Data System (TIRADS) was developed to improve patient management and cost-effectiveness by avoiding unnecessary fine needle aspiration biopsy (FNAB) in patients with thyroid nodules. However, its clinical use is still very limited. Strain elastography (SE) enables the determination of tissue elasticity and has shown promising results for the differentiation of thyroid nodules.
Methods: The aim of the present study was to evaluate the interobserver agreement (IA) of TIRADS developed by Horvath et al. and SE. Three blinded observers independently scored stored images of TIRADS and SE in 114 thyroid nodules (114 patients). Cytology and/or histology was available for all benign (n = 99) and histology for all malignant nodules (n = 15).
Results: The IA between the 3 observers was only fair for TIRADS categories 2–5 (Coheńs kappa = 0.27,p = 0.000001) and TIRADS categories 2/3 versus 4/5 (ck = 0.25,p = 0.0020). The IA was substantial for SE scores 1–4 (ck = 0.66,p<0.000001) and very good for SE scores 1/2 versus 3/4 (ck = 0.81,p<0.000001). 92–100% of patients with TIRADS-2 had benign lesions, while 28–42% with TIRADS-5 had malignant cytology/histology. The negative-predictive-value (NPV) was 92–100% for TIRADS using TIRADS-categories 4&5 and 96–98% for SE using score ES-3&4 for the diagnosis of malignancy, respectively. However, only 11–42% of nodules were in TIRADS-categories 2&3, as compared to 58–60% with ES-1&2.
Conclusions: IA of TIRADS developed by Horvath et al. is only fair. TIRADS and SE have high NPV for excluding malignancy in the diagnostic work-up of thyroid nodules.
Background: To compare the effect of aprotinin with the effect of lysine analogues (tranexamic acid and ε-aminocaproic acid) on early mortality in three subgroups of patients: low, intermediate and high risk of cardiac surgery.
Methods and Findings: We performed a meta-analysis of randomised controlled trials and observational with the following data sources: Medline, Cochrane Library, and reference lists of identified articles. The primary outcome measure was early (in-hospital/30-day) mortality. The secondary outcome measures were any transfusion of packed red blood cells within 24 hours after surgery, any re-operation for bleeding or massive bleeding, and acute renal dysfunction or failure within the selected cited publications, respectively.
Out of 328 search results, 31 studies (15 trials and 16 observational studies) included 33,501 patients. Early mortality was significantly increased after aprotinin vs. lysine analogues with a pooled risk ratio (95% CI) of 1.58 (1.13–2.21), p<0.001 in the low (n = 14,297) and in the intermediate risk subgroup (1.42 (1.09–1.84), p<0.001; n = 14,427), respectively. Contrarily, in the subgroup of high risk patients (n = 4,777), the risk for mortality did not differ significantly between aprotinin and lysine analogues (1.03 (0.67–1.58), p = 0.90).
Conclusion: Aprotinin may be associated with an increased risk of mortality in low and intermediate risk cardiac surgery, but presumably may has no effect on early mortality in a subgroup of high risk cardiac surgery compared to lysine analogues. Thus, decisions to re-license aprotinin in lower risk patients should critically be debated. In contrast, aprotinin might probably be beneficial in high risk cardiac surgery as it reduces risk of transfusion and bleeding complications.